DNOW vs XMTR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
DNOW presents a contradictory profile characterized by a very weak Piotroski F-Score of 2/9, indicating deteriorating fundamental health, despite a strong balance sheet with low debt (D/E 0.27) and high liquidity (Current Ratio 2.34). While revenue growth is explosive at 68% YoY, this has not translated to the bottom line, as evidenced by a -40% YoY decline in EPS and negative profit margins. The stock is trading near book value (P/B 1.06) and is viewed as a 'Strong Buy' by analysts, but the bearish technical trend and poor deterministic health scores suggest significant execution risk.
XMTR presents a classic growth-stage profile with a critical divergence between operational momentum and financial health. The Piotroski F-Score of 2/9 indicates significant fundamental weakness, yet the company has successfully pivoted toward profitability with a 166.7% YoY EPS growth and consistent earnings beats. While revenue growth remains strong at 29.5%, the bearish insider sentiment and high Price-to-Book ratio suggest the current valuation may be ahead of the underlying financial stability.
Compare Another Pair
Related Comparisons
DNOW vs XMTR: Head-to-Head Comparison
This page compares DNOW Inc. (DNOW) and Xometry, Inc. (XMTR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.